Selank dosing, like Semax, does not fit the injection-and-units model used for most research peptides. It is given intranasally, and its dosing comes from the Russian products where it is registered as an anxiolytic rather than from a Western clinical guideline. There is no FDA-sanctioned dose.[1][2]
Reviewed for accuracy · Last reviewed July 7, 2026In Russia, Selank is registered for generalized anxiety disorder and neurasthenia, and the dose depends on the specific product. The main human evidence is a small comparative trial against a benzodiazepine, not a large placebo-controlled program, so any specific figure rests on thin ground. Community anxiety-focused use cites various intranasal amounts, but these are extrapolation.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.